Protara Therapeutics (TARA) Capital Expenditures (2013 - 2025)

Protara Therapeutics (TARA) has 13 years of Capital Expenditures data on file, last reported at $24000.0 in Q4 2025.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $24000.0 in Q4 2025; TTM through Dec 2025 was $94000.0, a 108.89% increase from a year earlier, with the FY2025 full-year figure at $94000.0, up 49.21% from the prior year.
• Capital Expenditures for Q4 2025 stood at $24000.0, up from $4000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for TARA reached as high as $326000.0 in Q2 2021 and fell as low as -$64000.0 in Q3 2021.
• Historically, Capital Expenditures has averaged $53937.5 across 5 years, with a median of $21000.0 in 2022.
• Across the five-year window, Capital Expenditures jumped 5533.33% in 2021 and sank 96.21% in 2022, its largest moves.
• Year by year, Capital Expenditures stood at $44000.0 in 2021, then sank by 86.36% to $6000.0 in 2022, then jumped by 516.67% to $37000.0 in 2023, then sank by 78.38% to $8000.0 in 2024, then jumped by 200.0% to $24000.0 in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were $24000.0 in Q4 2025, $4000.0 in Q3 2025, and $22000.0 in Q2 2025.